Quinolones are broad-spectrum antibiotics active against both Gram-positive and Gram-negative bacteria, including mycobacteria, and anaerobes. Quinolone antibiotics changed the way infections are treated in human and veterinary medicine. Their unique pharmacological, microbiological and biochemical properties are unparalleled. Mutational resistance to quinolones emerged causing significant limitations and became linked to multidrug resistance with the emergence of plasmid-mediated mechanisms. In this discussion, we explore the opportunities and challenges these antimicrobials present and how to best use them in an ever-changing landscape.
- Robert Bonomo, MD, Associate Chief of Staff for Academic Affairs at Case Western Reserve University School of Medicine.
- Yonatan Grad, MD, Ph.D., Melvin J. and Geraldine L. Glimcher Associate Professor of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health.
- David Hooper, MD, Chief, Infection Control Unit, Associate Chief, Division of Infectious Diseases, Massachusetts General Hospital, Professor of Medicine, Harvard Medical School.
- Shaohua Zhao, Ph.D., MPVM, Senior Biomedical Research Service/Research Microbiologist, The U.S. Food & Drug Administration/Center for Veterinary Medicine.
- Amy Mathers, MD, D(ABMM), Associate Professor of Medicine and Pathology, University of Virginia, Medical Director Antimicrobial Stewardship, Associate Director of Clinical Microbiology.
- Laura Rojas, Ph.D., Senior Instructor, Department of Molecular Biology and Microbiology Case Western Reserve University School of Medicine, Leader of the Genomics Research Group at the Case Western Reserve University-Veterans Affairs Center for Antimicrobial Resistance and Epidemiology (Case VA CARES).
Supported in part through educational grants from: